Merck's (MRK.US) best-selling drug Keytruda met its main goal in late-stage ovarian cancer trial.

According to the Fintech News App, Merck (MRK.US) announced on Thursday that its top-selling treatment Keytruda, as part of a combination therapy, has met the primary endpoint in a phase 3 trial for a specific type of ovarian cancer.